BioPharma Drive: Drug Pricing

DECEMBER 2, 2024

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.

Licensing 284

Licensing Licensing Drugs 284

BioPharma Drive: Drug Pricing

MARCH 3, 2025

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

Licensing 250

Licensing Licensing Drug Development Drugs 250

BioPharma Drive: Drug Pricing

DECEMBER 12, 2023

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

Drug Research 304

Drug Research Licensing Licensing Research 304

Drug Patent Watch

JULY 30, 2024

The Power of Patent Licensing: Unlocking Innovation and Access to Medicines Patent licensing agreements have become a crucial tool in the pharmaceutical industry, allowing companies to collaborate and…

Licensing 105

Licensing Licensing Pharmaceuticals Drugs 105

BioPharma Drive: Drug Pricing

JANUARY 9, 2025

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind Biosciences, led by an oral therapy ready for Phase 2 testing.

Licensing 259

Licensing Licensing Therapies Drugs 259

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

Licensing 96

Licensing Licensing Drugs Biosimilars 96

BioPharma Drive: Drug Pricing

OCTOBER 18, 2024

European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.

Licensing 167

Licensing Licensing Regulations Drugs 167

BioPharma Drive: Drug Pricing

DECEMBER 4, 2024

Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy. Novo will pay $200 million to gain control of the protein manufacturing factory.

Licensing 144

Licensing Licensing Drugs Therapies 144

Science Daily: Pharmacology News

AUGUST 9, 2023

The drug tecovirimat is currently in use for the treatment of mpox -- the disease caused by monkeypox virus -- that spread worldwide in 2022. Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus.

Licensing 168

Licensing Licensing Treatment Virus 168

BioPharma Drive: Drug Pricing

OCTOBER 2, 2024

The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease but limited resources.

Licensing 157

Licensing Licensing Disease Drugs 157

BioPharma Drive: Drug Pricing

MARCH 3, 2025

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

Licensing 199

Licensing Licensing Therapies Drugs 199

BioPharma Drive: Drug Pricing

APRIL 2, 2024

A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.

Licensing 176

Licensing Licensing Drugs 176

BioPharma Drive: Drug Pricing

MAY 9, 2024

The deal gives the company milestone payments and royalties to a medicine, frexalimab, that Sanofi licensed from biotech ImmuNext and expects to be a future blockbuster.

Licensing 190

Licensing Licensing Drugs 190

BioPharma Drive: Drug Pricing

DECEMBER 19, 2024

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare conditon.

Licensing 157

Licensing Licensing Drugs 157

BioPharma Drive: Drug Pricing

JUNE 21, 2024

Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead. A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study.

Drug Development 167

Drug Development Licensing Licensing Drugs 167

BioPharma Drive: Drug Pricing

AUGUST 1, 2023

Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.

Licensing 130

Licensing Licensing Production Marketing 130

BioPharma Drive: Drug Pricing

NOVEMBER 9, 2023

The pharma paid $400 million to license the drug from Hutchmed earlier this year in an effort to bolster its oncology business.

FDA Approval 157

FDA Approval Licensing Licensing FDA 157

BioPharma Drive: Drug Pricing

APRIL 23, 2024

Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.

Licensing 167

Licensing Licensing Drugs 167

BioPharma Drive: Drug Pricing

JUNE 14, 2024

Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.

Licensing 157

Licensing Licensing Drugs 157

BioPharma Drive: Drug Pricing

JUNE 4, 2024

The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.

Licensing 176

Licensing Licensing Treatment Disease 176

BioPharma Drive: Drug Pricing

JUNE 18, 2024

With a drug licensed from Novartis, the new biotech startup aims to reduce the ‘remnant’ cholesterol it says existing medicines can’t address.

Licensing 176

Licensing Licensing Drugs 176

BioPharma Drive: Drug Pricing

JULY 12, 2024

Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, Ipsen is licensing an ADC and Novartis is closing a San Diego site.

Licensing 176

Licensing Licensing Drugs 176

BioPharma Drive: Drug Pricing

MARCH 3, 2025

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to treat polycythemia vera.

Licensing 130

Licensing Licensing Drugs 130

BioPharma Drive: Drug Pricing

OCTOBER 9, 2024

The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.

Licensing 167

Licensing Licensing Drugs 167

BioPharma Drive: Drug Pricing

NOVEMBER 27, 2024

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and another $325 million in equity investment.

Licensing 144

Licensing Licensing Drugs Research 144

Drug Discovery Today

JANUARY 26, 2022

a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. Saffron Walden, 26th January 2022 / Domainex Ltd.,

Licensing 100

Licensing Licensing Science Research 100

BioPharma Drive: Drug Pricing

FEBRUARY 14, 2024

The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.

Licensing 176

Licensing Licensing Marketing Drugs 176

BioPharma Drive: Drug Pricing

DECEMBER 18, 2024

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.

Licensing 157

Licensing Licensing Drug Development Drugs 157

BioPharma Drive: Drug Pricing

JULY 11, 2023

The pharma, which had largely exited the field several years ago, will pay nearly $100 million combined to the two biotechs for rights to several experimental candidates.

Licensing 111

Licensing Licensing Drugs 111

BioPharma Drive: Drug Pricing

OCTOBER 20, 2023

The deal is worth up to $22 billion in total, making it one of the largest pharmaceutical licensing agreements by value.

Licensing 157

Licensing Licensing Pharmaceuticals Drugs 157

BioPharma Drive: Drug Pricing

JANUARY 12, 2024

Showing reporters and industry veterans a demonstration of its new drug development software, Recursion said at J.P. Morgan it is now licensing its work to buyers.

Licensing 167

Licensing Licensing Drug Development Drugs 167

Broad Institute

OCTOBER 29, 2024

New drug triggers rapid cell death in cancer models By Karen Zusi-Tran October 29, 2024 Breadcrumb Home New drug triggers rapid cell death in cancer models BRD-810 inhibits the MCL1 protein and reactivates apoptosis in tumor cells, displaying therapeutic potential in animal models. The result was the compound named BRD-810.

Drugs 133

Drugs Small Molecule Pharmacokinetics Clinical Trials 133

BioPharma Drive: Drug Pricing

AUGUST 20, 2024

In addition to new stock offerings, this week saw Merck license an antibody drug conjugate and BARDA further work trying to innovate remote clinical trials.

Clinical Trials 144

Clinical Trials Licensing Licensing Trials 144

Collaborative Drug

JUNE 21, 2024

Burlingame, CA, June 21, 2024 — Collaborative Drug Discovery (CDD), a leading provider of data management solutions for the pharmaceutical and biotechnology industries, is pleased to announce the integration of iChemLabs' industry-leading IUPAC naming technologies into CDD Vault.

Licensing 147

Licensing Licensing Pharmaceuticals Drugs 147

Reprocell

SEPTEMBER 19, 2024

The biological license application (BLA) is one of the many requests for marketing approval received by the FDA. Unlike the New Drug Application (NDA) which is usually the go-to submission for chemically synthesized, low molecular weight drugs BLAs grant sponsors the ability to introduce Biologics into interstate commerce.

Licensing 59

Licensing Licensing Regulations FDA 59

Drug Patent Watch

OCTOBER 12, 2021

International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions. This paper was originally published by Md.

Production 105

Production Pharmaceuticals Licensing Licensing 105

Drug Patent Watch

JULY 13, 2020

Mudawi in the Journal of Pharmaceutical Research International under the terms of the Creative Commons Attribution License.…. The post Common Drugs with Effective Off-Label Uses appeared first on DrugPatentWatch - Make Better Decisions. This article was originally published by Mohammed M. Alshehri and Mahmoud M.

Licensing 94

Licensing Licensing Drugs International 94